AQST - Aquestive Therapeutics: Looking To End 2021 On A Bullish Note
- Aquestive Therapeutics is moving closer to Libervant’s PDUFA date in December. If approved, Aquestive will finish 2021 on a bullish note that can be sustained into 2022.
- Aquestive has fought through COVID-19 headwinds and was able to report a strong beat on Q3 with SYMPAZAN continuing to show strong growth over the past 11 consecutive quarters.
- The company’s AQST-109 epinephrine program reported impressive topline data from a PK study. If approved, AQST-109 could dethrone the EpiPen as the leader in the epinephrine market.
- I discuss my plans for managing my AQST position ahead of the PDUFA date and potential approval.
For further details see:
Aquestive Therapeutics: Looking To End 2021 On A Bullish Note